PDSB · PDS Biotechnology Corp
$0.23
0.00 (-1.11%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these uncertainties, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$12.91M
Shares
55.97M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$34.5M
+8.3%
FY2025
Diluted EPS
-$0.74
+28.2%
FY2025
Operating Cash Flow
-$27.75M
+20.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $15.7M | $19.03M | $22.57M | $27.76M | $29.43M | $11.25M | $7.92M | $6.1M | $830.74K | $34.31M | $24.83M | $17.84M | $8.47M | $4.48M | |
| $12.13M | $12.52M | $13.76M | $15.28M | $12.24M | $10.18M | $6.98M | $10.98M | $2.79M | $17.65M | $14.69M | $8.66M | $4.72M | $2M | |
| — | — | — | — | — | — | $15.61K | $98.41K | $69.12K | — | — | — | — | — | |
| — | — | — | — | — | — | — | $2.07M | $9.91M | $0 | — | — | — | — | |
| $27.83M | $31.54M | $36.32M | $43.05M | $41.67M | $21.44M | $14.9M | $21.03M | $3.65M | $51.97M | $39.51M | $26.5M | $13.19M | $6.49M | |
| -$27.83M | -$31.54M | -$36.32M | -$43.05M | -$41.67M | -$21.44M | -$14.9M | -$21.03M | -$3.65M | -$51.97M | -$39.51M | -$26.5M | -$13.19M | -$6.49M | |
| $6.66M | $5.34M | $4.67M | $4.21M | $1.32M | $0 | $0 | $33.56K | $3595 | $2.18M | $1.2M | $816.49K | $183.18K | $3354 | |
| $817.99K | $1.22M | $2.51M | $2.9M | $935.18K | $4346 | $55.01K | $353.49K | $0 | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | -$190.3K | — | — | — | — | — | |
| -$33.67M | -$35.67M | -$38.48M | -$44.35M | -$42.05M | -$21.43M | -$14.85M | -$7.38M | -$3.84M | -$53.45M | -$40.67M | -$29.19M | -$12.79M | -$7.34M | |
| $0 | -$1.17M | -$869.17K | -$1.41M | -$1.2M | -$4.52M | $0 | -$381.51K | $0 | -$2.59M | -$1.85M | -$1.11M | -$590.68K | -$459.02K | |
| -$33.67M | -$34.5M | -$37.61M | -$42.94M | -$40.85M | -$16.92M | -$14.85M | -$7M | -$3.84M | -$50.86M | -$38.82M | -$28.08M | -$12.2M | -$6.88M | |
| — | — | — | — | — | — | — | — | — | -$50.86M | -$38.82M | -$32.44M | -$13.78M | -$7.96M | |
| -$33.67M | -$34.5M | -$37.61M | -$42.94M | -$40.85M | -$16.92M | -$14.85M | -$7M | -$3.84M | -$50.86M | -$38.82M | -$28.08M | -$12.2M | -$6.88M | |
| USD/shares | — | -$0.74 | -$1.03 | -$1.39 | -$1.43 | -$0.66 | -$0.89 | — | — | — | — | — | — | — |
| USD/shares | — | -$0.74 | -$1.03 | -$1.39 | -$1.43 | -$0.66 | -$0.89 | — | — | — | — | — | — | — |
| shares | — | 46.38M | 36.45M | 30.95M | 28.6M | 25.6M | 16.75M | 4.87M | 3.34M | 30.39M | 28.86M | 8.09M | 1.69M | 1.69M |
| shares | — | 46.38M | 36.45M | 30.95M | 28.6M | 25.6M | 16.75M | 4.87M | 3.34M | 30.39M | 28.86M | 8.09M | 1.69M | 1.69M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.16×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.05×
Peer medians compare against the 210 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
1472091
CUSIP
70465T107
13F (30d)
49 filings
49 filers
Visit website
Investor relations